durvalumab (Imfinzi)

following a full submission assessed under the end of life and orphan equivalent medicine process:

durvalumab (Imfinzi®) is accepted for use within NHSScotland

Indication under review: in combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with:

• durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)
• durvalumab in combination with olaparib in endometrial cancer that is mismatch repair proficient (pMMR).

In a double-blind, randomised, phase III study, progression-free survival was significantly improved with the addition of durvalumab to chemotherapy followed by durvalumab maintenance with or without olaparib compared with chemotherapy alone in patients with primary advanced or recurrent endometrial cancer.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.